AQST (Aquestive Therapeutics) Stocks and Options Tracker

AQST

(NASDAQ)

4.84

-0.37 (-7.10%)

Pre-market: .00 -4.84 (-100.00%)

Volume (24h)	Market Cap.	Day Range	52w Range
568.74K	162.72M	4.76 - 5.17	1.41 - 10.00

Oct-28-20 04:33PM	Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks
Oct-19-20 11:21AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST): Is Breakeven Near?Simply Wall St.
Oct-14-20 11:30AM	Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ETGlobeNewswire
Sep-30-20 03:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Aquestive Therapeutics, Inc. (AQST) InvestigationACCESSWIRE
Sep-29-20 10:06PM	Aquestive Therapeutics: Libervant Will Eventually Be Approved, Says AnalystTipRanks
Sep-28-20 08:25AM	Aquestive Plunges 37% As FDA Rejects Seizure Drug; Street Stays BullishSmarterAnalyst
Sep-25-20 09:38PM	Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure ClustersGlobeNewswire
12:51PM	Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock OptionsZacks
Sep-17-20 02:11PM	3 “Strong Buy” Healthcare Stocks With Major Catalysts ApproachingTipRanks
Aug-20-20 12:11PM	Are Insiders Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock?Simply Wall St.
11:30AM	Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including AnaphylaxisGlobeNewswire
Aug-18-20 03:06PM	Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% HigherZacks
Aug-10-20 11:30AM	Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including AnaphylaxisGlobeNewswire
Aug-05-20 10:31PM	Aquestive Therapeutics, Inc. (AQST) Q2 2020 Earnings Call TranscriptMotley Fool
Aug-04-20 11:35PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue EstimatesZacks
08:01PM	Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date ApproachesGlobeNewswire
Aug-04-20 12:18PM	The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial PlansBenzinga
Jul-28-20 08:15PM	Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswire
04:33PM	Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks
Jul-15-20 11:57AM	Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ETGlobeNewswire
Jul-06-20 01:49PM	What Is The Ownership Structure Like For Aquestive Therapeutics, Inc. (NASDAQ:AQST)?Simply Wall St.
Jun-29-20 11:00AM	Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentGlobeNewswire
Jun-25-20 03:22PM	Hedge Funds Aren’t Crazy About Aquestive Therapeutics, Inc. (AQST) AnymoreInsider Monkey
Jun-16-20 12:00PM	Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare ConferenceGlobeNewswire
Jun-04-20 09:05PM	Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of StockholdersGlobeNewswire
May-28-20 01:42PM	Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock OptionsZacks
May-27-20 01:22PM	Why Aquestive Therapeutics (AQST) Stock Might be a Great PickZacks
May-22-20 11:10AM	The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID FrayBenzinga
May-21-20 09:27PM	Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA ApprovalGlobeNewswire
May-20-20 03:30PM	Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?Zacks
May-14-20 12:25PM	Aquestive Therapeutics' Shares March Higher, Can It Continue?Zacks
May-12-20 04:00PM	All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to BuyZacks
May-08-20 12:15PM	Benzinga Pro's Top 5 Stocks To Watch For Fri., May 8, 2020: KC, IDXX, LAZY, AQST, ANBenzinga
May-07-20 06:00PM	Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare ConferenceGlobeNewswire
May-06-20 10:00PM	Aquestive Therapeutics, Inc. (AQST) Q1 2020 Earnings Call TranscriptMotley Fool
May-05-20 08:05PM	Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On TrackGlobeNewswire
Apr-28-20 04:34PM	Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should KnowZacks
Apr-26-20 11:51AM	3 Biotech Stocks Under $4 With Big Upside PotentialTipRanks
Apr-21-20 01:15PM	Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6GlobeNewswire
Apr-15-20 12:50PM	Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate RevisionsZacks
Apr-14-20 01:13PM	Top Ranked Momentum Stocks to Buy for April 14thZacks
Mar-17-20 11:00AM	Memgen Appoints Gregory Brown as Chief Executive OfficerNewsfile
Mar-14-20 12:15PM	Aquestive Therapeutics, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?Simply Wall St.
Mar-13-20 02:23PM	Company News for Mar 13, 2020Zacks
Mar-11-20 10:25PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue EstimatesZacks
08:30PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsGlobeNewswire
Mar-03-20 08:00PM	7 Cheap Stocks Under $7 With Massive Upside PotentialKiplinger
Feb-20-20 12:00PM	Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020GlobeNewswire
Feb-10-20 12:00PM	Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal FilmGlobeNewswire
Feb-06-20 12:00PM	Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentGlobeNewswire

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

More Discussions

Confucius · October 30, 2020

good day to add; this got a few month of wait time, but at least a double and then more for those patient enough to wait...

Upvote: 1 · Downvote: 0 · Replies: 0

justin · October 30, 2020

With markets and volume like this, this is what you get. Doesn’t matter to me this will rise soon enough. Always buy on red days. GLTA

Upvote: 1 · Downvote: 1 · Replies: 0

justin · October 30, 2020

@sdale are you only here to dislike my comments or do you want to add something to this forum? If you disagree, please show us some insight from your side..

Upvote: 1 · Downvote: 0 · Replies: 0

justin · October 29, 2020

Aquestive deserves more love imo! Hopefully earnings can draw some attention to new buyers! Volume is soooo low..

Upvote: 0 · Downvote: 0 · Replies: 0

justin · October 28, 2020

Talking about volatility lol.. good buy opportunities occurring. Good luck

Upvote: 2 · Downvote: 1 · Replies: 0

dick · October 28, 2020

We should make a run at 5.80 soon

Upvote: 2 · Downvote: 0 · Replies: 0

PACK ATTACK · October 27, 2020

I was able to add more at 5.09 bought and sold portion several times this is a 14 to $30 stock

Upvote: 0 · Downvote: 0 · Replies: 0

AA · October 27, 2020

The whole S&P is down this will rebound. I am hoping for another stimulus for the world.

Upvote: 2 · Downvote: 0 · Replies: 0

dick · October 26, 2020

Its breaking the chains... a nice slow climb would be welcomed!

Upvote: 2 · Downvote: 0 · Replies: 0

Kash · October 23, 2020

Picked up some shares on this drop !!

Upvote: 2 · Downvote: 0 · Replies: 0

justin · October 23, 2020

Can’t wait till volume is picking up! That is when the real fun starts.

Upvote: 2 · Downvote: 1 · Replies: 0

dick · October 21, 2020

As we sit right now.... we got a upside gap of 5.54-7.40. I plan on having 50% position going into earnings! I think there is a good chance of clearing the gap to the $6.90 area.... that would test the 200mda. That would leave a gap 6.90 to 7.40 to close in the future! There is still some catalyst that can come up to close it before year end! The stock showed some really good support above $4.60 after a dip to $4.41. I am feeling good about the short term now... and plan on buying more before earnings! I did not get any of the recent cheap shares in the 4.60 range.... but I am comfortable buying low $5s right now... time will tell?? Good luck

Upvote: 1 · Downvote: 2 · Replies: 0

dick · October 20, 2020

I took a 25% stake today! Chart starting to form!

Upvote: 0 · Downvote: 0 · Replies: 0

KenRz · October 20, 2020

looking good for 5.80

Upvote: 2 · Downvote: 0 · Replies: 0

Rajen · October 15, 2020

Recently AQST won a patent infringement case against BDSi for the drug named belbuca.Do you think this will help SP when AQST get the punitive damage money from bdsi and may be royalty money.Any feedback?

Upvote: 2 · Downvote: 3 · Replies: 2

Paul · October 14, 2020

need a solid close above $5.22 before this thing starts to march higher. YCMV

Upvote: 1 · Downvote: 0 · Replies: 0

dick · October 14, 2020

Good to see the stock show some strength with decent volume!

Upvote: 1 · Downvote: 1 · Replies: 0

Tig · October 14, 2020

Earning should get us to the 6 range...IMHO.

Upvote: 2 · Downvote: 0 · Replies: 0

Hulk · October 14, 2020

Still patiently waiting for the strike. It may never happen, but that is why it is called hunting?Looking for sub 4 sometime before year end...FYI, I am bullish on the company overall and think this makes a nice recovery by mid next year, but am weary of a substantial dip in the interim.

Upvote: 2 · Downvote: 4 · Replies: 0

Chris · October 13, 2020

Let's go!

Upvote: 3 · Downvote: 0 · Replies: 0

Open in Yahoo | Open in Google | Open in Finviz